Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the AstraZeneca drug Evusheld for immunosuppressed people in the UK; what plans he has to use that drug as a (a) prophylactic and (b) treatment; and what his timeline is for the rollout of that drug for use in the UK.
We continue to monitor the emerging data for AstraZeneca’s long-acting antibody therapy, AZD7442, also known as Evusheld. AstraZeneca have discussed potential approvals with the Medicines and Healthcare products Regulatory Agency .
The Department published a Prior information Notice (PIN) on 5 October 2021 inviting suppliers to submit an expression of interest on neutralising antibody treatments being developed for treating and preventing COVID-19. The PIN is accessible by suppliers and enables the Department to undertake a fair and transparent market engagement process with suppliers. We are unable to provide further information on the deployment of Evusheld as it is commercially sensitive.